logo
Plus   Neg
Share
Email

Bristol-Myers Says Phase 3 CheckMate -331 Study Fails To Meet Primary Endpoint

Bristol-Myers Squibb Company (BMY) today announced results from the Phase 3 CheckMate -331 study evaluating Opdivo or nivolumab versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung cancer or SCLC who relapsed following platinum-based chemotherapy. The study did not meet its primary endpoint of overall survival or OS with Opdivo versus chemotherapy.

The safety profile of Opdivo in this trial was consistent with that observed in previously reported monotherapy studies involving patients with SCLC.

Bristol-Myers Squibb has a broad development program in thoracic malignancies, including SCLC, non-small cell lung cancer and malignant pleural mesothelioma. As part of this program, the Company is investigating the role of Opdivo plus Yervoy and Opdivo monotherapy versus placebo in the frontline setting as a maintenance therapy for patients with SCLC who do not progress on first-line chemotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Bank of Canada (RY, RY.TO) reported that its first-quarter net income to shareholders increased to C$3.10 billion from C$2.93 billion, a year ago. Earnings per share was C$2.15 compared to C$2.01. Adjusted EPS was C$2.19 compared to C$2.05. On average, 12 analysts polled by Thomson Reuters expected... Google added bitcoin's 'B' symbol to its Keyboard on iOS devices, indicating the leading cryptocurrency's growing acceptance in the mainstream industry. The feature, however, is not added to Android keyboards. The addition of the bitcoin currency key reflects Google users' growing interest in bitcoin. According to Google Trends, 'What is Bitcoin?' was the most popular search question in 2018. Shares of Deutsche Telekom AG were losing around 2 percent in German trading after the telecom giant reported Thursday a net loss in its fourth quarter, compared to prior year's profit, despite increased revenues. Looking ahead, the company said its 2019 forecast shows undiminished growth momentum.
Follow RTT